Dr. Gerald Sokol Co-Authors Five Studies To Be Published / Presented at ASCO Annual Meeting
- June 1, 2018
- No responses
Hudson, FL – May 31, 2018 . . . Dr. Gerald Sokol, who practices at the Florida Cancer Specialists (FCS) location inHudson, FL is the co-author of five studies that will be published and/or presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago, IL, June 1 – 5, 2018. Expected to draw over 30,000 attendees, the ASCO annual meeting is the largest gathering of oncologists in the world. This year’s theme is “Delivering Discoveries: Expanding the Reach of Precision Medicine.”
One of the studies in which Dr. Sokol participated has been selected as an Abstract Presentation for the session on Gastrointestinal (Non-colorectal) Cancer that will be held on Sunday, June 3. The Abstract focuses on the use of SM-88 in advanced pancreatic cancer (PC). According to its developing company, SM-88 is a “novel combination therapy that disrupts the metabolic processes of cancer cells and makes them vulnerable to oxidative stress and death.” SM-88 has previously “demonstrated efficacy in both prostate and breast cancers with no significant toxicity or serious adverse events.”
As stated in the Abstract, current treatment options for “recurrent/refractory advanced pancreatic cancer include largely ineffective toxic therapies or palliation.” Early signals from the ongoing clinical trials for the use of SM-88 in advanced PC look promising, with initial data demonstrating prolonged survival rates, weight gain/maintenance and a reduction in, or maintenance of, pain scores.
Dr. Sokol is board certified in both medical oncology and radiation oncology, as well as internal medicine, quality assurance and utilization review and clinical pharmacology. After earning his medical degree at Indiana University, he completed his internship and residency at Harvard Medical School, Massachusetts General Hospital in Boston, Temple University Hospital in Philadelphia and the U.S. Public Health Service Hospital, in affiliation with John Hopkins University, the University of Maryland and the National Cancer Institute. Dr. Sokol has served as a medical officer at the Center for Drug Evaluation and Research, Food and Drug Administration in Washington, DC, and is a captain in the United States Navy Reserve. He is also Associate Professor of Medicine & Clinical Pharmacology at the Uniformed Services University of the Health Sciences at Walter Reed.
To access Abstracts:
About Florida Cancer Specialists & Research Institute: (FLCancer.com)
Founded in 1984, Florida Cancer Specialists & Research Institute (FCS) is the largest independent medical oncology/hematology practice in the United States. With more than 220 physicians, 180 nurse practitioners and physician assistants and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings close to home.
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, FCS offers patients access to more clinical trials than any private oncology practice in Florida. In the past 3 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report. Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan-Kettering, the physicians of Florida Cancer Specialists provide leadership and consultation in the state’s leading hospitals.
FCS serves patients on the Gulf Coast from Naples to the greater Tampa Bay area, north as far as Tallahassee, in Orlando and surrounding Central Florida communities, and on the East Coast from Palm Beach County to the Jacksonville area.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research and cutting-edge technologies that help advance targeted treatments and genetically-based immunotherapies, and embodied by our outstanding team of highly-trained and dedicated physicians, clinicians and staff.
* Prior to approval
For More Information, Contact:
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer – SGlenn@FLCancer.com
Chris Wilkerson – email@example.com
Ganick Communications, Inc.
Elaine Ganick – firstname.lastname@example.org